| Literature DB >> 25534001 |
Naresh Kumar1, Pankaj Attri1, Dharmendra Kumar Yadav2, Jinsung Choi1, Eun Ha Choi1, Han Sup Uhm1.
Abstract
Recently, atmospheric-pressure non-thermal plasma-jets (APPJ) are being for the cancer treatment. However, APPJ still has drawbacks such as efficiency and rise in temperature after treatment. So, in this work, a synergetic agent D2O vapour is attached to APPJ which not only increase the efficiency of plasma source against cancer treatment, but also controlled the temperature during the treatment. OD generated by the combination of D2O + N2 plasma helped in enhancing the efficiency of APPJ. We observed OD induced apoptosis on melanocytes G361 cancer cells through DNA damage signalling cascade. Additionally, we observed that plasma induces ROS, which activated MAPK p38 and inhibits p42/p44 MAPK, leading to cancer cell death. We have also studied DNA oxidation by extracting DNA from treated cancer cell and then analysed the effects of OD/OH/D2O2/H2O2 on protein modification and oxidation. Additionally, we attempted molecular docking approaches to check the action of D2O2 on the apoptosis related genes. Further, we confirmed the formation of OD/OH simultaneously in the solution using optical emission spectroscopy. Moreover, the simultaneous generation of D2O2/H2O2 was detected by the use of confocal Raman spectroscopy and density measurements.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25534001 PMCID: PMC4274518 DOI: 10.1038/srep07589
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic diagram of D2O + N2 plasma jet device and its OES spectra (A) A plasma jet system consisting mainly of a high-voltage power supply, electrodes and dielectrics; (B) Shows vacuum chamber consists of vacuum pump which used to take out atmospheric gas from inside the chamber and then chamber was filled with nitrogen gas only; (C) D2O + N2 plasma jet device was used in this experiment. The distance between the cell media and outer electrode is kept as 3 to 4 mm during exposure; (D) Measurement optical emission spectra during treatment with plasma.
Figure 2pH, temperature and ROS/RNS measurements after plasma exposure in media (A) Measurement of pH, (B) Temperature in 1 ml of RPMI media were exposed to N2 plasma and D2O + N2 plasma for different time interval 1, 3, 5 and 10 min; (C) Determination of OH concentration; (D) Determination of H2O2 concentration; (E) NO in 1 ml media after N2 and D2O + N2 plasma exposure for 1, 3, and 5 min only. All values are expressed as ± SD in triplicates. Students' t-test was performed to control (* denotes P<0.05 and ** denotes P<0.01).
Figure 3(a) Raman spectra of the H2O (black), D2O (red), D2O + N2 plasma (blue) after binding with titanyl ion after 5 min; (b) Raman spectra of the H2O (black), D2O (red), D2O + N2 plasma (blue) after binding with titanyl ion to check the conformation of D2O2; (c) Determination of H2O2 concentration in 1 ml water solution after D2O + N2plasma exposure for 3 and 5 min. All values are expressed as ± SD in triplicates. Students' t-test was performed to control (* denotes P<0.05 and ** denotes P<0.01).
Figure 4Viability of G361 cells treated with (A) D2O + N2 plasma; (B) N2 plasma (C) cell viability during different time intervals after plasma treatment with D2O + N2 plasma. Viability of plasma treated cells was measured after 3, 6, 9, 12 and 24 h incubation by MTT assay; (D) Early and late apoptosis analysis through flow cytometry after Annexin V-FITC/PI staining of plasma treated G361cells; (E) The normalized cell number distribution to Annexin V-FITC/PI intensity of G361 cells was plotted by plasma exposure time. Actinomycin D was used to make positive control. All values are expressed as ± SD in triplicates. Students' t-test was performed to control (* denotes P<0.05 and ** denotes P<0.01).
Figure 5Intracellular ROS estimation and apoptotic related gene expression analyses (A) The level of intracellular ROS after D2O + N2 plasma exposure for 0 min (control), 3 min and ROS scavenger trolox + 3 min treatment. All values are expressed as mean fluorescence intensity (MFI) and ± SD in triplicates; (B) Qualitative analysis of the intracellular ROS level after plasma treatment through fluorescence microscopy using fluorescent probes H2DCFDA; (C) The relative value of mRNA expression of nine apoptosis and related genes of G361melanocytes cancer cells after plasma exposure for 3 min with and without presence of trolox. The relative mRNA expression of p53, Caspase-8, ATM, Bax and NOX(1-5) subfamily were measured by real-time RT-PCR on day 1 and 18s rRNA was used as a reference gene. All values are expressed as (MFI) and ± SD in triplicates. Students' t-test was performed to control (* denotes P<0.05 and ** denotes P<0.01).
Figure 6DNA oxidation and genomic DNA modification analyses.
Melanocytes G361 cancer cells were exposed to D2O + N2 plasma for 3 min and used for the analyses of DNA oxidation and genomic DNA modification through (A) Circular dichroism; (B) Production of 8-OHdG measured. Each value is the average of three technical replicates. Students' t-test was performed to control (*denotes P<0.05 and **denotes P<0.01); (C) 1%Agarose gel electrophoresis analysis of genomic DNA extracted from the treated G361cells.
Figure 7Protein oxidation and extracellular protein modification analyses (A) Mb; (B) Hb proteins were exposed to D2O + N2 plasma for different time intervals through circular dichroism; (C) SDS gel electrophoresis of treated Mb and Hb proteins for 5 min and 30% (v/v) H2O2 treatment; (D) Production of carbonyl content measured the treated protein with D2O + Nitrogen plasma for without treatment (control), 3 min, 5 min and 50 μM H2O2.Each value is the average of three technical replicates. Students' t-test was performed to control (* denotes P<0.05 and ** denotes P<0.01).
Secondary structure changes of Mb and Hb proteins, determined from CD spectra in different condition at 25°C determined
| Samples | α- sheet (%) | β-sheet (%) | Turn (%) | Random coil (%) |
|---|---|---|---|---|
| Mb control | 51 | 22 | 1 | 26 |
| 1 min | 41 | 20 | 15 | 23 |
| 3 min | 31 | 23 | 22 | 24 |
| 5 min | 25 | 29 | 19 | 26 |
| H2O2 | 26 | 38 | 0 | 35 |
| Hb control | 50 | 22 | 10 | 18 |
| 1 min | 49 | 20 | 10 | 20 |
| 3 min | 38 | 33 | 6 | 23 |
| 5 min | 30 | 31 | 7 | 31 |
| H2O2 | 12 | 49 | 0.4 | 38 |
Figure 8Backbone ribbon diagram of the Erk2 (A), p53 (B) and caspase-8 (C) heterodimer. Inhibitors are shown as in magnatacolor. Electrostatic potential mapped onto molecular surface for substrate binding-site (active pocket) of Erk2 (D), p53 (E) and caspase-8 (F). Inhibitors are shown as in green color in binding pocket site. In silico molecular docking studies elucidating the interaction of actinomycin D in the binding site of Erk2 (G), p53 (H) and Caspase-8 (I) protein. H2O2/D2O2 docked on target with total docking score 3.4751 (J), 3.7161 (K) and 2.6876 (L) show two H-bond of length 1.9 and 1.9 Å to binding pocket residue ASP-106 and MET-108, with Erk2, four H-bond of length 1.8,1.8, 1.9 and 2.0 Å to binding pocket residue GLY-154, THR-155, CYS-220 and GLU-221 with p53 and two H-bond of 2.1 Å to binding pocket residue GLU-396 with caspase-8 within selection radius of 4Å from bound substrate revealing the binding site pocket of active conformation.
Comparison of binding affinity of D2O2/H2O2, Actinomycin D and Norathyriol and against Erk2, p53 and Caspase-8 receptor protein
| Inhibitor/Compound | Target protein/PDB ID | Total Score | Amino acid involved in active pocket in 4 Ă | Involved group of Amino Acid | Length of H-bond Ă | No. of Hydrogen Bond |
|---|---|---|---|---|---|---|
| H2O2 (Test substrate) | Erk2/3SA0 | 3.4751 | ILE-31, ALA-52, ILE-84, GLN-106, ASP-106, LEU-107, MET-108, LEU-156 | ASP-106 MET-108 | 1.951.90 | 2 |
| p53/3ZME | 3.7161 | PRO-153, GYS-154, THR-155, ARG-156, ARG-202, PRO-219, CYS-220, GLU-221 | GLY-154THR-155CYS-220GLU-221 | 1.861.881.992.00 | 4 | |
| Caspase-8/3KJQ | 2.6876 | GLU-396, PHE-399, THR-469 | GLU-396 | 2.132.15 | 2 | |
| Actinomycin (positive control) | Erk2/3SA0 | 1.0890 | TYR-30, ILE-31, GLY-32, GLU-33, GLY-34, ALA-35, VAL-39, GLU-109, THR-110, ASP-111, TYR-113, LYS-114, LEU-115, LYS-117, LEU-156 | - | - | - |
| p53/3ZME | 3.4505 | THR-150, PRO-153, ARG-202, GLU-221, PRO-222, PRO-223, GLU-224, VAL-225 | - | - | ||
| Caspase-8/3KJQ | 3.3725 | PRO-322, TYR-334, GLU-335, SER-338, GLN-339, THR-341, LYS-344, GLU-396, THR-467, THR-469 | LYS-344 | 1.99 | 1 | |
| Norathyriol | Erk2/3SA0 | 4.4761 | GLY-34, VAL-39, ALA-52, LYS-54, ILE-84, GLN-105, ASP-106, LEU-107, MET-108, ASP-111, LYS-114, LEU-156 | MET-108ASP-106GLN-105 | 1.832.031.96 | 3 |
| QC5 | p53/3ZME | 4.6541 | LEU-145, VAL-147, ASP-148, THR-150, PRO-151, PRO-152, PRO-153, CYS-220, GLU-221, PRO-222, THR-230 | - | - | - |
| B94 | Caspase-8/3KJQ | 3.8974 | TYR-334, THR-337, SER-338, GLU-396, PHE-399, THR-467, PHE-468, THR-469 | - | - | - |
Primer sequences used for evaluation of the mRNA expression
| Genes | Forward primers [5-3] | Reverse primers [5-3] |
|---|---|---|
| 18S rRNA | AACGAGACTCTGGCATGCTAACTA | CGCCACTTGTCCCTCTAAGAA |
| p53 | CACATGACGGAGGTTGTGAG | ACACGCAAATTTCCTTCCAC |
| Caspase8 | TTGAACCCAAGAGGTCAAGG | ACGGGGTCTTGTTCTGTCAC |
| ATM | GGGCAACATGGTGAAACTCT | CCTTAACCTCCAGGGCTCAG |
| Bax | AACATGGAGCTGCAGAGGAT | CAGTTGAAGTTGCCGTCAGA |
| NOX1 | CCACTGTAGGCGCCCTAAGTT | ATGACCGGTGCAAGGATCC |
| NOX2 | GCCCAAAGGTGTCCAAGC | TCCCCAACGATGCGGATAT |
| NOX3 | CCTTCTGTAAAGACCGCTATGCA | GACCACAGGGCCTAAAATCCA |
| NOX4 | ACCCTGTTGGATGACTGGAA | ACCAACGGAAAGGACTGGATA |
| NOX5 | CAGGCACCAGGAAAAGAAAGCAT | TGTTGATCCAGATAAAGTCCACCTT |